search
Back to results

A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics (CHF6001_POC2)

Primary Purpose

Asthma

Status
Completed
Phase
Phase 2
Locations
United Kingdom
Study Type
Interventional
Intervention
CHF6001
Placebo
Sponsored by
Chiesi Farmaceutici S.p.A.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring PDE4 inhibitor, Allergen Challenge, Asthma

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • written informed consent obtained
  • Non smoking or ex-smokers from at least 1 year prior to study entry
  • Males of females between 18 and 60 years inclusive
  • Body Mass Index between 18 and 32 kg/m2
  • Ability to be trained about the proper use of the inhalation device and to perform spirometry
  • With mild to moderate allergic asthma as defined by the GINA guideline, steroid naive
  • Atopy to at least one common aeroallergen
  • Positive allergen-induced Early Asthmatic Response and Late Asthmatic Response at screening
  • Ability to produce an adequate sputum sample
  • Post-menopausal women, women of not childbearing potential or males and females of childbearing potential willing (they or their partner) to use a reliable method of contraception.

Exclusion Criteria:

  • Worsening of asthma or respiratory tract infection prior to study entry
  • History of life-threatening asthma or hospitalization for asthma prior to the study entry
  • Pregnant or lactating women
  • History of clinically significant hypotensive episodes or fainting, dizziness or light-headedness
  • History or symptoms of clinically relevant neurologic disease
  • Symptomatic hay fever
  • Unstable concurrent disease that may impact the feasibility of the study
  • Use of systemic corticosteroids, nebulised bronchodilator or oral beta2-agonist
  • Use of leukotrienes modifiers, roflumilast or cromoglycate
  • Use of long acting beta2-agonist or inhaled corticosteroids
  • Use of short-acting or long-acting non-sedatives antihistamines
  • Use of any other medication for the treatment of allergic asthma other than salbutamol
  • Having received an investigational medicinal drug within 30 days prior to study entry
  • Blood drawn of at least 250 ml in the previous 45 days
  • Ongoing use of tobacco
  • Other lung disease
  • Recent history of alcohol dependency
  • Inability to comply with the study protocol

Sites / Locations

  • Hammersmith Medicines Research
  • Respiratory Clinical Trials
  • Medicines Evaluation Unit

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Experimental

Experimental

Arm Label

Placebo DPI

CHF6001 DPI Dose 2

CHF6001 DPI Dose1

Arm Description

Placebo by inhalation for 9 days

CHF6001 by inhalation for 9 days

CHF6001 by inhalation for 9 days

Outcomes

Primary Outcome Measures

Allergen challenge

Secondary Outcome Measures

Induced Sputum
Methacholine challenge

Full Information

First Posted
September 4, 2012
Last Updated
March 28, 2017
Sponsor
Chiesi Farmaceutici S.p.A.
search

1. Study Identification

Unique Protocol Identification Number
NCT01689571
Brief Title
A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics
Acronym
CHF6001_POC2
Official Title
A Randomised, Double-blind, Placebo-controlled, Three-way Crossover Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Two Doses of Inhaled CHF6001 DPI After 9 Days of Treatment in Adult Patients With Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
October 2012 (undefined)
Primary Completion Date
April 2013 (Actual)
Study Completion Date
April 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chiesi Farmaceutici S.p.A.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The study is designed to look at the safety, tolerability and efficacy of 2 different doses of the study drug (CHF6001, a PDE4 inhibitor) in asthmatics, when given by inhalation, once a day for 9 days. The efficacy will be evaluated by measuring the protective effect of CHF 6001 after an allergen challenge.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
PDE4 inhibitor, Allergen Challenge, Asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
36 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo DPI
Arm Type
Placebo Comparator
Arm Description
Placebo by inhalation for 9 days
Arm Title
CHF6001 DPI Dose 2
Arm Type
Experimental
Arm Description
CHF6001 by inhalation for 9 days
Arm Title
CHF6001 DPI Dose1
Arm Type
Experimental
Arm Description
CHF6001 by inhalation for 9 days
Intervention Type
Drug
Intervention Name(s)
CHF6001
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Allergen challenge
Time Frame
after 9 days of treatment
Secondary Outcome Measure Information:
Title
Induced Sputum
Time Frame
After 9 days of treatment
Title
Methacholine challenge
Time Frame
After 9 days of treatment
Other Pre-specified Outcome Measures:
Title
Pharmacokinetics of CHF6001 and its metabolites
Description
The following parameters will be evaluated at the steady state: AUC0-t, AUC0-24h, Cmax, Cmin, Cav, tmax, tmin, t½, CL/F and Vz/F
Time Frame
after 9 days of treatment
Title
Vital signs
Time Frame
After single dose and 9 days of treatment
Title
ECG
Time Frame
After single dose and 9 days of treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: written informed consent obtained Non smoking or ex-smokers from at least 1 year prior to study entry Males of females between 18 and 60 years inclusive Body Mass Index between 18 and 32 kg/m2 Ability to be trained about the proper use of the inhalation device and to perform spirometry With mild to moderate allergic asthma as defined by the GINA guideline, steroid naive Atopy to at least one common aeroallergen Positive allergen-induced Early Asthmatic Response and Late Asthmatic Response at screening Ability to produce an adequate sputum sample Post-menopausal women, women of not childbearing potential or males and females of childbearing potential willing (they or their partner) to use a reliable method of contraception. Exclusion Criteria: Worsening of asthma or respiratory tract infection prior to study entry History of life-threatening asthma or hospitalization for asthma prior to the study entry Pregnant or lactating women History of clinically significant hypotensive episodes or fainting, dizziness or light-headedness History or symptoms of clinically relevant neurologic disease Symptomatic hay fever Unstable concurrent disease that may impact the feasibility of the study Use of systemic corticosteroids, nebulised bronchodilator or oral beta2-agonist Use of leukotrienes modifiers, roflumilast or cromoglycate Use of long acting beta2-agonist or inhaled corticosteroids Use of short-acting or long-acting non-sedatives antihistamines Use of any other medication for the treatment of allergic asthma other than salbutamol Having received an investigational medicinal drug within 30 days prior to study entry Blood drawn of at least 250 ml in the previous 45 days Ongoing use of tobacco Other lung disease Recent history of alcohol dependency Inability to comply with the study protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dave Singh, MD
Organizational Affiliation
Medicines Evaluation Unit
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Brian Leaker, MD
Organizational Affiliation
Respiratory Clinical Trials
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Elizabeth Tranter, MD
Organizational Affiliation
Hammersmith Medicines Research
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hammersmith Medicines Research
City
London
Country
United Kingdom
Facility Name
Respiratory Clinical Trials
City
London
Country
United Kingdom
Facility Name
Medicines Evaluation Unit
City
Manchester
Country
United Kingdom

12. IPD Sharing Statement

Links:
URL
https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001483-29
Description
Study Record on EU Clinical Trials Register including results

Learn more about this trial

A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics

We'll reach out to this number within 24 hrs